Porphyromonas gingivalis: a gum-disease suspect healthy mouths carry

There is a bacterium living in the narrow, wet groove between your tooth and your gum that has no interest whatsoever in sugar. Give it a doughnut and it will not touch it. What it wants is protein — yours — and it carries a set of molecular knives to get at it. It has been one of the most heavily studied organisms in the human mouth for decades, and the more closely researchers look at it, the stranger the picture becomes: it is common in healthy mouths, and it is the organism most consistently blamed for the disease that destroys them.

What it is, in one sentence

Porphyromonas gingivalis is a Gram-negative, anaerobic, asaccharolytic rod of the order Bacteroidales that colonises the space beneath the gum line and is the best-documented example of what microbiologists call a keystone pathogen ¹².

Unpack "asaccharolytic" and you have most of its biology. The organism cannot ferment sugars for energy. It grows on peptides, and it requires haem — the iron-carrying core of your haemoglobin — as its iron source ². That single metabolic fact explains almost everything else about it. A bacterium that eats protein and needs blood iron does best in a pocket that is inflamed, seeping and bleeding. It has no reason to build such a pocket by accident.

Where it lives

Its home address is the subgingival crevice: the biofilm on the tooth root and on the epithelium lining the pocket. It attaches to adsorbed salivary molecules, to matrix proteins, to epithelial cells, and to bacteria already established there; binding to all of these substrates may, the review's authors propose, be mediated by various regions of fimbrillin, the structural subunit of its major fimbriae ². It does not stop at the surface. By modulating host cell signal transduction it can direct its own uptake into gingival epithelial cells and replicate inside them — a privileged site from which, the same review says, it impinges upon components of the innate host defence ².

Whether it belongs anywhere else in the body is a live question rather than a settled fact. The same review notes accumulating evidence that infection may predispose to cardiovascular disease and to preterm delivery ², and a 2019 report identified the organism and its enzymes in the brains of people who died with Alzheimer's disease ⁷. Detecting a bacterium at a site is not the same as showing it drives what happens there, and I will come back to that.

What it does for us

Here the honest answer is short: nothing that has been demonstrated. There is no established benefit of Porphyromonas gingivalis to human health — no vitamin it supplies, no pathogen it excludes, no metabolite we depend on. If I told you otherwise I would be inventing it.

What can be said, and is worth saying loudly, is that carrying it is not the same as being harmed by it. One major review describes the organism as an opportunist that can also exist in commensal harmony with the host, with disease episodes following a shift in the ecological balance of the pocket rather than the simple arrival of the bug ². The prevalence data agree. In one survey using immunofluorescence, the organism was found in 85.7 % of subjects with periodontal disease and in 23.1 % of healthy subjects ³. In a more recent study using real-time PCR, it was detected in 91.5 % of chronic periodontitis patients and in 58 % of healthy individuals ⁴. Counting by site rather than by person, an older checkerboard study found it at a mean of 23 % of sampled sites in periodontitis patients and 4 % of sites in healthy people ⁵.

Notice that those healthy-carriage figures — 23.1 % ³ and 58 % ⁴ — disagree with each other by a factor of more than two. That is not a scandal; it is what happens when different laboratories use different detection methods on different populations. A sensitive PCR finds DNA that immunofluorescence misses. The number to take away is not any single percentage but the shape of all of them: the organism is more common in disease, and it is nonetheless present in a substantial share of mouths that are perfectly well.

What it does against us

The weapons are proteases called gingipains. There are two specificities: one cuts protein chains after arginine, the other after lysine, and neither is easily inhibited by your own host protease inhibitors ⁸. Uncontrolled proteolysis of that kind has consequences that map neatly onto what a dentist sees. Arginine-gingipain activates the kallikrein-kinin pathway, producing oedema, and activates complement, pulling neutrophils in. Lysine-gingipain degrades fibrinogen, producing bleeding ⁸. Increased crevicular flow, neutrophil accumulation and bleeding on probing are three of the classic signs of periodontitis.

The keystone idea goes further. In animal models, even at low colonisation levels, the organism manipulates the crosstalk between complement and Toll-like receptors in a way that changes the counts and composition of the surrounding commensal microbiota; the resulting dysbiotic community, not the keystone species alone, then drives inflammatory bone loss ⁹¹. The effect is disproportionate to the abundance — which is precisely why counting cells tells you so little.

Two systemic links are worth naming, with their limits attached. First, arthritis: of the oral bacteria tested in one study, this was the only one that citrullinated proteins, using its own peptidylarginine deiminase to convert the carboxy-terminal arginine residues to citrulline after its arginine-gingipains cut the protein at Arg-X bonds — generating exactly the kind of altered self-antigen that the rheumatoid arthritis immune response attacks ⁶. Second, dementia: the 2019 study already mentioned found gingipains in Alzheimer's brains at levels that correlated with tau and ubiquitin pathology, and showed that oral infection in mice led to brain colonisation and increased amyloid-beta production ⁷.

Both findings are mechanistically serious. Neither is proof of causation in humans. The citrullination work shows a plausible route, not that the route is taken in patients. The Alzheimer's work combines post-mortem human correlation with a mouse model, and twelve of its twenty-six authors, including the first three, were employees of the company developing the gingipain inhibitor — a fact you can read off the paper's own author affiliations, and one that belongs in your assessment of it. The bacterium is a strong suspect. It has not been convicted.

The name, new and old

The organism was first described in the genus Bacteroides, as Bacteroides gingivalis Coykendall et al. 1980. In 1988, Shah and Collins removed it and its relatives from that genus and placed them in a newly created genus, Porphyromonas ¹⁰. Porphyromonas gingivalis is therefore the current valid name; Bacteroides gingivalis is a synonym you will still meet in older papers and textbooks. NCBI Taxonomy and the List of Prokaryotic names with Standing in Nomenclature both list it at species rank in the family Porphyromonadaceae, order Bacteroidales, phylum Bacteroidota — the phylum formerly written Bacteroidetes.

What remains uncertain

Three things, said plainly. We do not know how often carriage — simply having the organism — progresses to destruction of gum and bone, or in whom. We do not know whether the keystone mechanism — one organism at low numbers tipping the whole community, as shown in animal models — operates the same way in human mouths; the authors of the keystone review ask that question themselves rather than assuming the answer ⁹. And we do not know whether the systemic associations — the links to arthritis and dementia beyond the mouth — reflect cause, consequence, or a shared underlying susceptibility to inflammation: whether the bug drives the disease, rides along with it, or both spring from the same inflammation-prone body. Those are the honest edges of the map, and pretending they are filled in would be the fastest way to mislead you.